DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia (Q35116184)

6 August 2017

1 reference

title

DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia (English)

1 reference

6 August 2017

0 references

1 reference

1

Arthur E Frankel

1 reference

6 August 2017

Donald R Fleming

2

1 reference

6 August 2017

Bayard L Powell

series ordinal

3

1 reference

6 August 2017

Ronald Gartenhaus

series ordinal

4

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Expert Opinion on Biological Therapy

6 August 2017

1 reference

6 August 2017

3

1 reference

6 August 2017

1

1 reference

6 August 2017

179-186

1 reference

Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data

6 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Alternate signalling pathways from the interleukin-2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

The crystal structure of diphtheria toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Molecular characterization of key diphtheria toxin:receptor interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Penetration of protein toxins into cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Fusion protein toxins based on diphtheria toxin: selective targeting of growth factor receptors of eukaryotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

The interleukin-2 and interleukin-4 receptors studied by molecular modelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.179

21 January 2018

Identifiers

DOI

10.1517/14712598.3.1.179

1 reference

6 August 2017

1 reference